Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy

[1]  G. Wenning,et al.  Animal models of multiple system atrophy , 2005, Clinical Autonomic Research.

[2]  P. Remy,et al.  Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration , 2011, Neurobiology of Aging.

[3]  B. Hyman,et al.  Distinct Roles In Vivo for the Ubiquitin–Proteasome System and the Autophagy–Lysosomal Pathway in the Degradation of α-Synuclein , 2011, The Journal of Neuroscience.

[4]  K. Jellinger,et al.  Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts , 2011, Acta Neuropathologica.

[5]  S. Waxman,et al.  Slowly Progressive Axonal Degeneration in a Rat Model of Chronic, Nonimmune-Mediated Demyelination , 2010, Journal of neuropathology and experimental neurology.

[6]  W. Poewe,et al.  Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure , 2010, Experimental Neurology.

[7]  B. Trapp,et al.  Demyelination Increases Axonal Stationary Mitochondrial Size and the Speed of Axonal Mitochondrial Transport , 2010, The Journal of Neuroscience.

[8]  P. Jenner,et al.  A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy , 2010, Brain Research.

[9]  K. Jellinger,et al.  Papp–Lantos inclusions and the pathogenesis of multiple system atrophy: an update , 2010, Acta Neuropathologica.

[10]  R. Seth,et al.  Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. , 2010, Biochemical pharmacology.

[11]  W. Möbius,et al.  Electron microscopy of the mouse central nervous system. , 2010, Methods in cell biology.

[12]  Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. , 2010, Current Alzheimer research.

[13]  G. Wenning,et al.  Multiple system atrophy: an update , 2009, The Lancet Neurology.

[14]  J. Middeldorp,et al.  Intermediate filament transcription in astrocytes is repressed by proteasome inhibition , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[16]  K. Jellinger,et al.  Multiple system atrophy: A primary oligodendrogliopathy , 2008, Annals of neurology.

[17]  Klaus-Armin Nave,et al.  Axon-glial signaling and the glial support of axon function. , 2008, Annual review of neuroscience.

[18]  M. Umeda,et al.  Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice , 2008, Cellular and Molecular Neurobiology.

[19]  W. Poewe,et al.  Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy , 2007, Movement disorders : official journal of the Movement Disorder Society.

[20]  C. Ide,et al.  Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[21]  A. Landau,et al.  Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle , 2007, Movement disorders : official journal of the Movement Disorder Society.

[22]  P. Jenner,et al.  Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats , 2006, Annals of neurology.

[23]  J. Cooper,et al.  Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons , 2006, Annals of neurology.

[24]  J. Langston,et al.  Lack of nigrostriatal pathology in a rat model of proteasome inhibition , 2006, Annals of neurology.

[25]  J. Kordower,et al.  Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.

[26]  Jeffrey H Kordower,et al.  Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.

[27]  O. Ottersen,et al.  Immunolocalization of BK channels in hippocampal pyramidal neurons , 2006, The European journal of neuroscience.

[28]  A. Brusco,et al.  Morphometric study on cytoskeletal components of neuronal and astroglial cells after chronic CB1 agonist treatment. , 2006, Methods in molecular medicine.

[29]  I. Amende,et al.  Journal of Neuroengineering and Rehabilitation Open Access Gait Dynamics in Mouse Models of Parkinson's Disease and Huntington's Disease Gait Variabilitygaitmouse Modelsneurodegenerationmovement Disordersamyotrophic Lateral Sclerosissod1 , 2022 .

[30]  T. Tanaka,et al.  α-Synuclein-positive structures induced in leupeptin-infused rats , 2005, Brain Research.

[31]  Werner Poewe,et al.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. , 2005, The American journal of pathology.

[32]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[33]  Carmen Birchmeier,et al.  Axonal Neuregulin-1 Regulates Myelin Sheath Thickness , 2004, Science.

[34]  J. Culvenor,et al.  α-synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy , 2003, Experimental Neurology.

[35]  P. Elliott,et al.  Proteasome inhibition: a new anti-inflammatory strategy , 2003, Journal of Molecular Medicine.

[36]  K. Nave,et al.  Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination , 2003, Nature Genetics.

[37]  J. Culvenor,et al.  alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. , 2003, Experimental neurology.

[38]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[39]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[40]  W. Spooren,et al.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. , 2002, EMBO reports.

[41]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[42]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[43]  D. German,et al.  Degeneration of neurons and glia in the Niemann–Pick C mouse is unrelated to the low-density lipoprotein receptor , 2001, Neuroscience.

[44]  J. Trojanowski,et al.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. , 2001, The American journal of pathology.

[45]  H. Hinterhuber,et al.  Synaptic loss reflected by secretoneurin‐like immunoreactivity in the human hippocampus in Alzheimer's disease , 1998, The European journal of neuroscience.

[46]  M. Clayton,et al.  The temporal progression of the myelination defect in the taiep rat , 1997, Journal of neurocytology.

[47]  T M Mayhew,et al.  If you assume, you can make an ass out of u and me': a decade of the disector for stereological counting of particles in 3D space. , 1996, Journal of anatomy.

[48]  W. Stoffel,et al.  Adhesive properties of proteolipid protein are responsible for the compaction of CNS myelin sheaths , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.